Telix at ANZSNM Annual Scientific Meeting 2024

Melbourne (Australia) | 23 April 2024

Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs at the 54^th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2024), being held in Christchurch (New Zealand) from 26-28 April 2024.

Presentations cover: TLX591 (¹⁷⁷Lu rosopatamab tetraxetan), Telix’s lead investigational radio antibody-drug conjugate (rADC) therapy for prostate cancer; Illuccix® (⁶⁸Ga-PSMA-11), Telix’s approved PET imaging agent for prostate cancer; and TLX250-CDx (⁸⁹Zr-DFO-girentuximab, Zircaix®¹), Telix’s investigational PET imaging agent for kidney cancer.

In addition, we are pleased to host a Breakfast Session on the latest innovations in theranostics and once again support the Nurses Workshop in collaboration with the Prostate Cancer Foundation of Australia (PCFA), NeuroEndocrine Cancer Australia (NECA) and the Peter MacCallum Cancer Centre in Melbourne.

Come and meet with us in person at booths 29 and 30 to discuss Telix’s extensive late-stage theranostic pipeline in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning, our associated medical devices and artificial intelligence (AI), along with opportunities for collaboration.

Details of ANZSNM ASM 2024 abstract presentations related to Telix programs are listed below and the full congress program can be accessed here.

Title: Lutetium-177 labelled anti-PSMA monoclonal antibody (TLX591, ¹⁷⁷Lu rosopatamab tetraxetan) therapy for metastatic prostate cancer: real-world data on treatment toxicity and outcomes

Presenter: Hanh Nguyen, Fiona Stanley Hospital (Perth, Western Australia)

Date and Time: Friday 26 April, 2024 | 5:00 pm – 5:15 pm (NZT)

Session: Therapy Session

Format: Oral Presentation

Location: Te Pae Auditorium